Neutropenia Potentially Associated With Remifentanil Administered for Respiratory Drive Suppression: A Case Report

Remifentanil-related neutropenia (< 500/μL) has not been previously described. We encountered it in an 81-year-old man after aortic surgery complicated by acute respiratory distress syndrome. While receiving remifentanil at 0.04-0.08 μg/kg/min to suppress excessive respiratory effort in the intensive care unit, his neutrophil count plummeted from 20,690/μL to 2400/μL. Suspect drugs were stopped and granulocyte colony-stimulating factor given, yet neutropenia persisted until remifentanil was withdrawn, after which neutrophils recovered. When respiratory status deteriorated, remifentanil was restarted, and neutropenia promptly recurred. The temporal relationship, dechallenge, and rechallenge strongly implicate remifentanil as the cause of this rare adverse reaction. This case highlights the need for vigilance regarding hematologic toxicity with any medication, even those without prior reports, and underscores the importance of prompt review and withdrawal of potential offending agents when severe neutropenia develops.

Authors

Institutions

Publication Details

Journal
Clinical Case Reports
Published
2026-02-01
DOI
https://doi.org/10.1002/ccr3.72000
Citations
1
Primary Topic
Blood disorders and treatments
Type
article
Field-Weighted Citation Impact
30.93
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Neutropenia Potentially Associated With Remifentanil Administered for Respiratory Drive Suppression: A Case Report

Hideko Watanabe, Kimito Minami, Muneyuki Takeuchi
1 citations
Clinical Case Reports
Blood disorders and treatments
30.93
article

Neutropenia Potentially Associated With Remifentanil Administered for Respiratory Drive Suppression: A Case Report

Hideko Watanabe, Kimito Minami, Muneyuki Takeuchi
article en
1 citations

Abstract

Remifentanil-related neutropenia (< 500/μL) has not been previously described. We encountered it in an 81-year-old man after aortic surgery complicated by acute respiratory distress syndrome. While receiving remifentanil at 0.04-0.08 μg/kg/min to suppress excessive respiratory effort in the intensive care unit, his neutrophil count plummeted from 20,690/μL to 2400/μL. Suspect drugs were stopped and granulocyte colony-stimulating factor given, yet neutropenia persisted until remifentanil was withdrawn, after which neutrophils recovered. When respiratory status deteriorated, remifentanil was restarted, and neutropenia promptly recurred. The temporal relationship, dechallenge, and rechallenge strongly implicate remifentanil as the cause of this rare adverse reaction. This case highlights the need for vigilance regarding hematologic toxicity with any medication, even those without prior reports, and underscores the importance of prompt review and withdrawal of potential offending agents when severe neutropenia develops.

Clinical Case ReportsVol. 14(2)
National Cerebral and Cardiovascular Center (JP)
Good health and well-being
Openalex Percentile: Top 1%
Blood disorders and treatments
30.93
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.